In hormone receptor-positive breast cancers, PPARγ activity generally restrains proliferation, whereas in aggressive triple-negative subtypes it supports metabolic reprogramming that fuels tumor survival and dissemination (132, 138). Here, PPARG is linked to breast cancer.